Cited by 20Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

Structural Determinant of β-Amyloid Formation: From Transmembrane Protein Dimerization to β-Amyloid Aggregates

Open access
Papadopoulos, Nicolas, Suelves, Nuria, Perrin, Florian, Vadukul, Devkee M., Vrancx, Céline, Constantinescu, Stefan N., Kienlen-Campard, Pascal·2022·Biomedicines

Published version of a preprint

Abstract

Most neurodegenerative diseases have the characteristics of protein folding disorders, i.e., they cause lesions to appear in vulnerable regions of the nervous system, corresponding to protein aggregates that progressively spread through the neuronal network as the symptoms progress. Alzheimer’s disease is one of these diseases. It is characterized by two types of lesions: neurofibrillary tangles (NFTs) composed of tau proteins and senile plaques, formed essentially of amyloid peptides (Aβ). A combination of factors ranging from genetic mutations to age-related changes in the cellular context converge in this disease to accelerate Aβ deposition. Over the last two decades, numerous studies have attempted to elucidate how structural determinants of its precursor (APP) modify Aβ production, and to understand the processes leading to the formation of different Aβ aggregates, e.g., fibrils and oligomers. The synthesis proposed in this review indicates that the same motifs can control APP function and Aβ production essentially by regulating membrane protein dimerization, and subsequently Aβ aggregation processes. The distinct properties of these motifs and the cellular context regulate the APP conformation to trigger the transition to the amyloid pathology. This concept is critical to better decipher the patterns switching APP protein conformation from physiological to pathological and improve our understanding of the mechanisms underpinning the formation of amyloid fibrils that devastate neuronal functions.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/biomedicines10112753

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Authors
Papadopoulos, N., Suelves, N., Perrin, F., Vadukul, D. M., Vrancx, C., Constantinescu, S. N., & Kienlen-Campard, P.
Affiliations
  • Ludwig Cancer Research (BE)
  • Aging and Dementia Research Group, Cellular and Molecular (CEMO) Division, Institute of Neuroscience, UCLouvain, 1200 Brussels, Belgium
  • Harvard University (US)
  • Imperial College London (GB)
  • VIB-KU Leuven Center for Brain & Disease Research (BE)
Venue
Biomedicines
Publisher
MDPI AG
Published
2022-10-29
Volume
10
Issue
11
Pages
2753
ISSN
2227-9059 (ISSN-L)
OpenAlex
W4307943470
Cited by
20
References
12
Citations by year
2026: 2 · 2025: 6 · 2024: 4 · 2023: 7 · 2022: 1
FWCI
0.62
Type
journal article
Language
en
Open access
Locations
  • Biomedicines (publishedVersion, cc-by)
  • Preprints.org (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Lirias (KU Leuven) (submittedVersion, cc-by)
  • Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)) (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Université catholique de Louvain (PDRT.0177.18, ARC 21/26-114)
  • FRS-FNRS (PDRT.0177.18, ARC 21/26-114)
  • Alzheimer Research Foundation (PDRT.0177.18, ARC 21/26-114)
  • Ludwig Institute for Cancer Research (PDRT.0177.18, ARC 21/26-114)
  • Fondation contre le cancer (PDRT.0177.18, ARC 21/26-114)
  • Salus Sanguinis and Fondation (PDRT.0177.18, ARC 21/26-114)
  • FWO postdoctoral fellowship (PDRT.0177.18, ARC 21/26-114)
  • SAO-FRA/Stop Alzheimer Research Foundation (PDRT.0177.18, ARC 21/26-114)
  • UCLouvain Action de Reechrche Concertée (PDRT.0177.18, ARC 21/26-114)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
amyloid-beta, Alzheimer's disease, amyloid precursor protein, protein dimerization, membrane protein dimerization, amyloid fibril formation, amyloid oligomers, protein folding disorders, neurofibrillary tangles, amyloid plaques, structural factors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review